Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

SLXN - Silexion Therapeutics Corp So'nggi... | Finranks

Home

/

SLXN

S

Silexion Therapeutics Corp (SLXN)

NCM – Real vaqt narxi. Valyuta: USD

0.47

-0.56 (-54.58%)

Bozor ochiq: Aug 12, 2026, 1:13 PM EDT

1.08

+0.04 (4.35%)

Oldingi bozordan keyin: Aug 11, 2026, 7:59 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about August 13, 2026, subject to the satisfaction of customary closing conditions.

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers

Videolar

No Data

There is no data to display

Press-relizlar

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering

GRAND CAYMAN, Cayman Islands, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of 3,846,161 of the Company's ordinary shares (or ordinary share equivalents) and series E warrants to purchase up to 3,846,161 ordinary at a combined public offering price of $0.65 per share (or per ordinary share equivalent) and accompanying warrants. The series E warrants will have an exercise price of $0.65 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The closing of the offering is expected to occur on or about August 13, 2026, subject to the satisfaction of customary closing conditions.

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers

Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers Silexion to present SIL-204 data at leading Cancer Symposium designed to feature the latest science in the field of GI cancers